

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re the Application of:

DEL SOLDATO

Group Art Unit: 1614

Application No.: 09/926,327

Examiner: Not yet assigned

Confirmation No.: 5185

Filed: October 15, 2001

Attorney Dkt. No.: 108907-00021

For: PHARMACEUTICAL COMPOUNDS

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, D.C. 20231

December 5, 2001

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the information item(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each item(s) is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the item(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date or the date of filing a CPA, OR (b) before the mailing date of a first Office Action on the merits in the present application, or (c) accompanies a Request for Continued Examination. No certification or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).
- ☐ c. A check in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p). Please charge any fee deficiency or credit any overpayment to

TECH CENTER 1600/2900

DEC 07 2001


RECEIVED

IDS/HP  
1/30/02

Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.

- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check in the amount of \$130.00 in payment of the petition fee under 37 CFR §1.17(i)(1). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).
- ☒ 4. The relevance of the references is discussed in the present specification.

Respectfully submitted,

  
Douglas H. Goldhush  
Registration No. 33,125 27931

**Customer No. 004372**  
ARENT FOX KINTNER PLOTKIN & KAHN, PLLC  
1050 Connecticut Avenue, N.W.,  
Suite 400  
Washington, D.C. 20036-5339  
Tel: (202) 857-6000  
Fax: (202) 638-4810

DHG:scc

Enclosures: PTO-1449 Form; 10 References

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 108907-00021
<b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		APPLICANT <b>DEL SOLDATO</b>
		FILING DATE October 15, 2001



**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
AA						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION		
							YES	NO	PART.
	AB	0 549 318 A2	06/30/93	European			xx		
	AC	0 562 497 A1	09/29/93	European			xx		
	AD	0 578 494 A1	01/12/94	European			xx		
	AE	5-39261	02/19/93	Japan				xx	
	AF								

**OTHER REFERENCES** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AG	McCance & Huether, "Pathophysiology: The Biologic Basis for Disease in Adults and Children", Third Edition, Mosby, 1998, pp 48-54, 71-77 and 1025.
	AH	K. B. Schwarz, "Oxidative Stress During Viral Infection: A Review", Free Radical Biology & Medicine, vol. 21, no. 5, 1996, pp 641-649.
	AI	Goodman & Gilman, "The Pharmacological Basis of Therapeutics", 9th Edition, 1996, McGraw-Hill Health Professions Division, pp 1459-1465 and 1474.
	AJ	Martindale, "The Extrapharmacopeia", 30th Edition, 1993, pp. 712-723.
	AK	Nenseter et al, "Paracetamol Inhibits Copper Ion-Induced, Azo Compound-Initiated, and Mononuclear Cell-Mediated Oxidative Modification of LDL", Arteriosclerosis, Thombosis, and Vascular Biology, Vol. 15, No. 9, September 1995, pp. 1338-1344.
	AL	Baylis et al, "Chronic Blockade of Nitric Oxide Synthesis in the Rat Produces Systemic Hypertension and Glomerular Damage", J. Clin. Investigation, vol. 90, 1992, pp 278-281.

EXAMINER	DATE CONSIDERED
----------	-----------------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.